Showing 1 - 20 results of 42 for search 'Kenneth W Mahaffey', query time: 0.07s
Refine Results
-
1
-
2
-
3
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE by Giulia Ferrannini, Carol Pollock, Andrea Natali, Yshai Yavin, Kenneth W. Mahaffey, Ele Ferrannini
Published 2023-04-01
Article -
4
-
5
-
6
-
7
-
8
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure by Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo. J. L. Heerspink
Published 2022-09-01
Article -
9
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatme... by Emily C. O'Brien, Sunghee Kim, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Kenneth W. Mahaffey, Bernard J. Gersh, Jonathan P. Piccini, Eric D. Peterson
Published 2016-05-01
Article -
10
Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial by Taha Sen, Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Wayne Shaw, William Canovatchel, Michael K. Hansen, Hiddo J. L. Heerspink
Published 2021-12-01
Article -
11
Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop by Roberto Jun Arai, Irene de Lourdes Noronha, José Carlos Nicolau, Charles Schmidt, Gustavo Moreira de Albuquerque, Kenneth W. Mahaffey, Eduardo Moacyr Krieger, José Otávio Costa Auler Júnior
Published 2018-09-01
Article -
12
Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation by Christoph B. Olivier, MD, Stephanie K. Middleton, BS, Natasha Purington, MS, Sumana Shashidhar, MS, Jody Hereford, BSN, MS, Kenneth W. Mahaffey, MD, Mintu P. Turakhia, MD, MAS, FHRS
Published 2021-04-01
Article -
13
Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events by Alexander C. Fanaroff, Ghazala Haque, Betsy Thomas, Allegra E. Stone, Lynn M. Perkins, Matthew Wilson, W. Schuyler Jones, Chiara Melloni, Kenneth W. Mahaffey, Karen P. Alexander, Renato D. Lopes
Published 2020-04-01
Article -
14
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis by Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Severine Bompoint, Carolyn S. P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg J. Jardine, Bruce Neal
Published 2020-02-01
Article -
15
Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure by Abhinav Sharma, Jingjing Wu, Justin A. Ezekowitz, Gary Michael Felker, Jacob A. Udell, Paul A. Heidenreich, Gregg C. Fonarow, Kenneth W. Mahaffey, Adrian F. Hernandez, Adam D. DeVore
Published 2020-02-01
Article -
16
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatmen... by Kevin L. Thomas, Larry R. Jackson, Peter Shrader, Jack Ansell, Gregg C. Fonarow, Bernard Gersh, Peter R. Kowey, Kenneth W. Mahaffey, Daniel E. Singer, Laine Thomas, Jonathan P. Piccini, Eric D. Peterson
Published 2017-12-01
Article -
17
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF by Emily C. O'Brien, DaJuanicia N. Holmes, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Jack E. Ansell, Kenneth W. Mahaffey, Bernard J. Gersh, Eric D. Peterson, Jonathan P. Piccini, Elaine M. Hylek
Published 2018-06-01
Article -
18
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial by Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G. B. John Mancini, Norman C. Wong, April Slee, Fernando G. Ang, Wally Rapattoni, Brendon L. Neuen, Clare Arnott, Vlado Perkovic, Kenneth W. Mahaffey
Published 2024-02-01
Article -
19
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease by Michael Szarek, Connie Hess, Manesh R. Patel, W. Schuyler Jones, Jeffrey S. Berger, Iris Baumgartner, Brian Katona, Kenneth W. Mahaffey, Lars Norgren, Juuso Blomster, Frank W. Rockhold, Judith Hsia, F. Gerry R. Fowkes, Marc P. Bonaca
Published 2022-06-01
Article -
20
Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagre... by Jennifer A. Rymer, Hillary Mulder, Kim G. Smolderen, William R. Hiatt, Michael S. Conte, Jeffrey S. Berger, Lars Norgren, Kenneth W. Mahaffey, Iris Baumgartner, F. Gerry Fowkes, Brian G. Katona, Frank Rockhold, W. Schuyler Jones, Manesh R. Patel
Published 2020-10-01
Article